Researchers reported an engineered feeder cell line that sharply increases allogeneic NK cell production, addressing a major bottleneck in adoptive cell therapy manufacturing. Using an optimized ARH-77 feeder platform expressing multiple stimulatory ligands, the team reported up to 101,241-fold NK expansion over 28 days, far exceeding performance from unmodified ARH-77 or conventional K562 feeders in comparable settings.